Next Phase Newsletter

A China-based venture capital investor manages seven USD funds with limited partners from prestigious academic institutions and hospital systems in the United States. The firm is capable of investing at any stage, from seed to pre-IPO. While the firm manages USD funds, it is rooted in China and is particularly interested in opportunities with a China angle or involving Asian founders. 

The firm has previously invested at the intersection of AI and healthcare, such as AI-driven drug discovery, diagnostics, and imaging, but has broadened its scope to include therapeutics. The firm is particularly interested in novel modalities, including drug conjugates, radiopharmaceuticals, and cell and gene therapies. The firm is open to various indications, prioritizing those with considerable market potential, such as oncology, immunology, CNS, pain management, and kidney diseases. In terms of development phases, the firm prefers companies from IND to clinical phases but is willing to consider companies in the PCC phase at the earliest. 

The firm prefers companies with strong management teams, particularly those with industry experience in pharma or biotech. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a venture capital investor headquartered in the US. The firm is currently investing from its third fund and allocates half of its capital into life science investments. The firm invests in Seed and Series A stages, with a typical check size of $1 million and up to $3 million in total after follow-on investments. The firm invests in four to five new companies each year and focuses on opportunities within the United States. 

The firm invests primarily in therapeutics and is also open to medical devices, molecular-based diagnostics, and digital health. The firm is indication- and modality-agnostic. 

The firm has no specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital investor makes equity investments ranging from a few hundred thousand dollars to $3 million, with additional capital reserved for follow-on rounds. The firm is seeking companies located throughout the United States and plans to make two to three new investments over the next 9–12 months. The firm invests in both seed-stage and later-stage companies. 

The firm is interested in companies developing medical devices and diagnostics, healthcare IT products, and life science research tools, with an emphasis on fast-to-market, low-capital-intensity products that reduce the cost of delivering quality healthcare. The firm is open to all sub-sectors and indications in the medical technology space, except for those targeting diseases and disorders of the spine. 

The firm seeks companies with skilled and experienced management teams. The firm generally takes a board seat after investment and plays an active role in the management. The firm is willing to invest in both public and privately held companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

This venture capital firm invests in pre-seed to seed stage opportunities with initial check sizes ranging from $500k to $1M and maintains reserves for follow-on capital. While the firm prefers to lead deals, it is open to syndication. Investment geography spans both Europe and the United States. 
 

The investment team has a deep technical background in software, artificial intelligence, and algorithms. Within life sciences and healthcare, the firm is focused on techbio, synthetic biology, computational biology, chemistry & materials. 

The firm is also open to hardware (e.g., diagnostics or medical devices) that enable novel data modalities, digital health, and therapeutic platforms. 

However, the firm does not invest in traditional therapeutic assets and is indication-agnostic. Opportunities can be considered as early as the pre-prototype stage, provided there is a roadmap toward intellectual property or patent protection. 

There are no strict team or company prerequisites, though the firm has a preference for technical founders with strong scientific grounding. The firm may take a board or observer seat depending on the opportunity. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

This venture capital fund was established by a group of high-net-worth individuals in China and maintains operations in the US and China. The firm is actively seeking global investment opportunities, with a primary focus on China and the United States. Opportunities based in Canada, Germany, and Switzerland may also be considered. 

The firm invests from seed and early stages through growth, with flexibility on check size for early-stage deals. For growth-stage companies, the firm typically invests $1-5M in equity in businesses with valuations up to $18-20M. Investments at earlier stages may take the form of equity or convertible notes. Thanks to an evergreen fund structure, the firm is able to take a long-term investment approach. It usually syndicates investments and seeks to partner with local co-investors, particularly for overseas deals. 

 
The firm targets high-growth sectors, including medical devices, diagnostics (e.g., portable imaging, high-intensity ultrasound, point-of-care, molecular diagnostics), digital health (particularly connected devices, telemedicine, and patient-physician platforms relevant to the Chinese market), and consumer products, especially OTC products, nutritional and dietary supplements with proven efficacy and existing market presence. 
 

The firm is indication-agnostic and prioritizes serial entrepreneurs and complete, well-rounded founding teams. It relies on local co-investors to play supervisory roles in international ventures. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An investment firm headquartered in China invests in both fund-of-funds and direct equity opportunities. Life sciences and healthcare represent one of its primary focus areas, though the firm maintains a multi-sector approach. Its investment sweet spot begins at the pre-A stage and extends through to pre-IPO. While the firm primarily targets opportunities within China, it is open to global companies, particularly those seeking a soft landing in China or with a strong China angle. The firm is flexible on deal structure and is open to both leading investments and co-investments. 

Within the healthcare and life sciences sector, the firm is especially interested in biotech therapeutics and medtech. On the therapeutics side, it is open to a range of modalities (excluding mRNA) and indications, with particular interest in areas such as central nervous system (CNS) disorders and oncology. On the medical device side, the firm prioritizes innovative technologies, including invasive solutions, imaging platforms, and brain-computer interfaces. It does not invest in non-innovative categories such as consumables. 

The firm does not maintain strict requirements regarding the background of founding teams, though it has a strong preference for companies that are interested in expanding into Shanghai or the broader Chinese market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An early-stage venture capital firm focuses on deeptech innovation, with strategic emphasis on the Cleantech and Biotech sectors. The firm acknowledges the critical role that advanced materials play in promoting both planetary and human health. 

The firm typically invests from Pre-Seed through Series A, with average initial allocations around USD $500k and reserves for follow-on participation. Geographically, the firm targets North America and Asia, and is also open to public-ready companies or those preparing to go public. 

Within biotech, the firm seeks novel therapeutics and global health-enhancing medical breakthroughs. While broadly sector-agnostic, the firm prioritizes companies with a technology backbone. Preferred areas include: platform technologies, enabling tools for drug discovery & development, and synthetic biology 

The firm is indication-agnostic, though generally less interested in infectious diseases. 

There are no strict team or company prerequisites, though the firm prefers to have an investor presence on the board. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology